Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial

NCT03213301 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03213301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2017
Completion date
June 11, 2021
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma, advanced